Heparin is back in the news, after France’s National Agency for Medicines and Health Products Safety issued a GMP noncompliance statement to China’s Dongying Tiandong Pharmaceutical, which manufactures the active ingredients of Lovenox and Heparin.
According to the statement, 10 deficiencies were observed during the inspection, two critical and three major. One critical deficiency involved polymerase chain reaction results of crude heparin that showed the presence of manipulated ruminant DNA. In addition, the quality system for ensuring full traceability of crude Heparin was “very weak.”
The company also was dinged for not understanding basic GMP principles for the handling of out-of-specification results and deviations. The statement cites seven batches of crude Heparin that were OOS for potency.
ANSM also chided the company for its process for evaluating new suppliers of crude heparin. Further, the assessments of 1 H NMR spectrum (heparin sodium) and 13 C NMR (enoxaparin sodium) used for identification testing were deficient, according to the statement.
Based on the investigator’s findings, ANSM is considering a recall of products from the plant.
Word of the findings comes roughly nine years after contaminated Heparin led to a number of adverse events, including deaths, in the U.S.
Stay up to date on regulatory stories like this one by subscribing to the Drug GMP Report. For over 20 years, drug manufacturers have relied on DGR for the latest on FDA’s interpretation and enforcement of cGMPs and the Quality Systems Regulation — information you need to stay in compliance.